Suppr超能文献

通过2型糖尿病和高血压患者步数处方进行步数监测以改善动脉健康(SMARTER):试验设计与方法

Step Monitoring to improve ARTERial health (SMARTER) through step count prescription in type 2 diabetes and hypertension: trial design and methods.

作者信息

Dasgupta Kaberi, Rosenberg Ellen, Daskalopoulou Stella S

机构信息

Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

出版信息

Cardiovasc Diabetol. 2014 Jan 6;13:7. doi: 10.1186/1475-2840-13-7.

Abstract

BACKGROUND

With increasing numbers of type 2 diabetes (DM2) and hypertension patients, there is a pressing need for effective, time-efficient and sustainable strategies to help physicians support their patients to achieve higher physical activity levels. SMARTER will determine whether physician-delivered step count prescriptions reduce arterial stiffness over a one-year period, compared with usual care, in sedentary overweight/obese adults with DM2/hypertension.

DESIGN

Randomized, allocation-concealed, assessor-blind, multisite clinical trial. The primary outcome is change in arterial stiffness over one year. The secondary outcomes include changes in physical activity, individual vascular risk factors, medication use, and anthropometric parameters. Assessments are at baseline and one year.

METHODS

Participants are sedentary/low active adults with 25 ≤ BMI < 40 kg/m2 followed for DM2/hypertension by a collaborating physician. The active arm uses pedometers to track daily step counts and review logs with their physicians at 3 to 4-month intervals. A written step count prescription is provided at each visit, aiming to increase counts by ≥3,000 steps/day over one year, with an individualized rate increase. The control arm visits physicians at the same frequency and receives advice to engage in physical activity 30-60 minutes/day. SMARTER will enroll 364 individuals to detect a 10 ± 5% difference in arterial stiffness change between arms. Arterial stiffness is assessed noninvasively with carotid femoral pulse wave velocity using applanation tonometry.

DISCUSSION

The importance of SMARTER lies not simply in the use of pedometer-based monitoring but also on its integration into a prescription-based intervention delivered by the treating physician. Equally important is the measurement of impact of this approach on a summative indicator of arterial health, arterial stiffness. If effectiveness is demonstrated, this strategy has strong potential for widespread uptake and implementation, given that it is well-aligned with the structure of current clinical practice.

TRIAL REGISTRATION

ClinicalTrials.gov (NCT01475201).

摘要

背景

随着2型糖尿病(DM2)和高血压患者数量的增加,迫切需要有效、省时且可持续的策略,以帮助医生支持患者提高身体活动水平。与常规护理相比,SMARTER研究将确定在为期一年的时间里,由医生开具的步数处方是否能降低久坐不动的超重/肥胖DM2/高血压成年患者的动脉僵硬度。

设计

随机、分配隐藏、评估者盲法、多中心临床试验。主要结局是一年中动脉僵硬度的变化。次要结局包括身体活动、个体血管危险因素、药物使用和人体测量参数的变化。评估在基线和一年时进行。

方法

参与者为久坐/低活动水平的成年人,体重指数(BMI)为25≤BMI<40kg/m²,由合作医生随访DM2/高血压情况。干预组使用计步器跟踪每日步数,并每3至4个月与医生复查记录。每次就诊时提供书面步数处方,目标是在一年内每天增加步数≥3000步,并按个性化速率增加。对照组以相同频率就诊,医生建议其每天进行30 - 60分钟的身体活动。SMARTER研究将招募364名个体,以检测两组间动脉僵硬度变化有10±5%的差异。使用压平式眼压计通过颈股脉搏波速度无创评估动脉僵硬度。

讨论

SMARTER研究的重要性不仅在于使用基于计步器的监测,还在于将其整合到由治疗医生提供的基于处方的干预中。同样重要的是测量这种方法对动脉健康的综合指标——动脉僵硬度的影响。如果证明该方法有效,鉴于其与当前临床实践结构高度契合,该策略具有广泛推广和实施的强大潜力。

试验注册

ClinicalTrials.gov(NCT01475201)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/615e/3893520/766d3818d1af/1475-2840-13-7-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验